OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
040156

Wanjia Group Holdings Ltd

Healthcare Facilities & ServicesVerified

Wanjia Group Holdings Ltd has a liquidity position characterized by a current ratio of 1.95, indicating a moderate ability to meet short-term obligations. The company holds HKD 24,083,000 in cash and equivalents, which is a significant portion of its total assets of HKD 106,822,000. However, the company reported negative operating income of HKD -4,089,000 and a net loss of HKD -6,616,000, suggesting operational challenges. The company's profitability metrics are below typical industry benchmarks. The return on equity (ROE) is -9.89%, and the return on assets (ROA) is -6.19%, both indicating poor capital efficiency and asset utilization. These figures are particularly concerning in the healthcare sector, where consistent returns are essential for sustaining operations and reinvestment. Wanjia Group Holdings Ltd operates through two primary segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consultancy services. The financial data does not provide a breakdown of revenue by segment, but the company's operations are likely concentrated in these two areas. There is no indication of geographic diversification in the provided data, suggesting potential revenue concentration risks. The company's growth trajectory is uncertain. The most recent financial data shows a net loss, and there is no indication of a significant revenue increase in the near term. The capital expenditure of HKD -732,000 suggests minimal investment in new projects or expansion, which could limit future growth opportunities. Risk factors for Wanjia Group Holdings Ltd include its negative net income and operating income, which could affect its ability to service debt and maintain operations. The company's debt-to-equity ratio of 0.32 is relatively low, indicating a conservative capital structure. However, the liquidity risk is classified as low, and there are no immediate filing-based liquidity or dilution flags. Recent events and filings do not indicate any significant changes in the company's operations or financial status. The absence of dilution flags and the low dilution risk suggest that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

30-day price · 0401+0.07 (+57.6%)
Low$0.12High$0.21Close$0.20As of22 May, 00:00 UTC
Profile
CompanyWanjia Group Holdings Ltd
Ticker0401.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Wanjia Group Holdings Ltd operates in the healthcare sector, primarily through pharmaceutical wholesale and distribution and hemodialysis treatment and consultancy services.

Classification. Wanjia Group Holdings Ltd is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Wanjia Group Holdings Ltd has a liquidity position characterized by a current ratio of 1.95, indicating a moderate ability to meet short-term obligations. The company holds HKD 24,083,000 in cash and equivalents, which is a significant portion of its total assets of HKD 106,822,000. However, the company reported negative operating income of HKD -4,089,000 and a net loss of HKD -6,616,000, suggesting operational challenges. The company's profitability metrics are below typical industry benchmarks. The return on equity (ROE) is -9.89%, and the return on assets (ROA) is -6.19%, both indicating poor capital efficiency and asset utilization. These figures are particularly concerning in the healthcare sector, where consistent returns are essential for sustaining operations and reinvestment. Wanjia Group Holdings Ltd operates through two primary segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consultancy services. The financial data does not provide a breakdown of revenue by segment, but the company's operations are likely concentrated in these two areas. There is no indication of geographic diversification in the provided data, suggesting potential revenue concentration risks. The company's growth trajectory is uncertain. The most recent financial data shows a net loss, and there is no indication of a significant revenue increase in the near term. The capital expenditure of HKD -732,000 suggests minimal investment in new projects or expansion, which could limit future growth opportunities. Risk factors for Wanjia Group Holdings Ltd include its negative net income and operating income, which could affect its ability to service debt and maintain operations. The company's debt-to-equity ratio of 0.32 is relatively low, indicating a conservative capital structure. However, the liquidity risk is classified as low, and there are no immediate filing-based liquidity or dilution flags. Recent events and filings do not indicate any significant changes in the company's operations or financial status. The absence of dilution flags and the low dilution risk suggest that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.
Key takeaways
  • Wanjia Group Holdings Ltd has a current ratio of 1.95, indicating a moderate ability to meet short-term obligations.
  • The company reported a net loss of HKD -6,616,000 and negative operating income of HKD -4,089,000, suggesting operational challenges.
  • The return on equity (ROE) is -9.89%, and the return on assets (ROA) is -6.19%, both indicating poor capital efficiency and asset utilization.
  • The company's operations are concentrated in two segments: pharmaceutical wholesale and distribution, and hemodialysis treatment and consultancy services.
  • The company's growth trajectory is uncertain, with minimal capital expenditure and no significant revenue increase in the near term.
  • The company has a low liquidity risk and no immediate filing-based liquidity or dilution flags.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$161.7M
Gross profit$50.3M
Operating income-$4.1M
Net income-$6.6M
R&D
SG&A
D&A
SBC
Operating cash flow$10.7M
CapEx-$732.0k
Free cash flow$914.0k
Total assets$106.8M
Total liabilities$39.9M
Total equity$66.9M
Cash & equivalents$24.1M
Long-term debt$21.7M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$66.9M
Net cash$2.4M
Current ratio1.9
Debt/Equity0.3
ROA-6.2%
ROE-9.9%
Cash conversion-1.6%
CapEx/Revenue-0.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric0401Activity
Op margin-2.5%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin-4.1%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin31.1%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-0.4%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity32.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 01:27 UTC#8193db7f
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 20:36 UTCJob: 57ce0cd9